<ѻýҕl>New Data Bolster Atezolizumab as Adjuvant Tx in NSCLCѻýҕl> Overall survival benefit now demonstrated Aug 09, 2022
<ѻýҕl>Low-Dose Sotorasib 'Lead-in' Strategy Promising in NSCLC Subsetѻýҕl> Early phase results set the stage for KRAS/immune-targeted combo as potential first-line option Aug 08, 2022
<ѻýҕl>Sublobar Resection the 'New Standard of Care' in Small-Sized NSCLC?ѻýҕl> Large randomized study shows non-inferiority to lobectomy Aug 08, 2022
<ѻýҕl>Young Adults With NSCLC More Apt to Get Advanced Disease Diagnosisѻýҕl> Study finds minimal improvements in the early diagnosis of young patients with lung cancer Aug 07, 2022
<ѻýҕl>More Help on the Way for Lung Cancers With Exon 20 Mutations?ѻýҕl> Early trials of DZD9008 demonstrated responses in over a third of patients Sep 15, 2021
<ѻýҕl>Cancer Vaccine May Boost Anti-EGFR Efficacy in Non-Small Cell Lung Cancerѻýҕl> More than 90% disease control rate, hint of improved PFS in pilot trial Sep 14, 2021
<ѻýҕl>Novel ADC Promising in Certain Non-Squamous Lung Cancersѻýҕl> Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression Sep 14, 2021
<ѻýҕl>More Data in Support of Surgery for Malignant Pleural Mesotheliomaѻýҕl> Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone Sep 13, 2021
<ѻýҕl>Meta-Analysis Confirms Benefits of Low-Dose CT Screening for Lung Cancerѻýҕl> LDCT associated with a 16% relative reduction in mortality versus no screening Sep 13, 2021
<ѻýҕl>Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLCѻýҕl> Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer Sep 12, 2021
<ѻýҕl>Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesotheliomaѻýҕl> Atezolizumab add-on offers promising outcomes in phase I trial Sep 12, 2021
<ѻýҕl>Durable Response with Immunotherapy Combos in NSCLC with Brain Metastasesѻýҕl> Analysis of CheckMate 9LA data and phase II study from Spain offer hope in advanced disease Sep 12, 2021
<ѻýҕl>Dual Immunotherapy Boosts Survival in Metastatic NSCLCѻýҕl> Benefit with durvalumab-tremelimumab may vary by PD-L1 expression, histology Sep 10, 2021
<ѻýҕl>Study Sheds Light on Physician-Assisted Suicide in Lung Cancer Patientsѻýҕl> Patients often did not consult with radiation or medical oncologists Sep 09, 2021
<ѻýҕl>Second-Line Combo Fails to Improve Survival in SCLCѻýҕl> No OS difference, but lurbinectedin-doxorubicin was less toxic than standard chemotherapy options Sep 09, 2021
<ѻýҕl>High Response Rate in Non-Small Cell Lung Cancer With RET Inhibitorѻýҕl> Responses in 66-80% of patients from China confirm activity of pralsetinib Sep 09, 2021
<ѻýҕl>TROP2 Antibody-Drug Conjugate Shows Promise in Lung Cancerѻýҕl> Disease control observed in over two-thirds of patients at selected dose Sep 08, 2021
<ѻýҕl>KRAS Inhibitor Continues to Impress in NSCLCѻýҕl> Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
<ѻýҕl>Nab-Paclitaxel as Possible Option for Relapsed NSCLCѻýҕl> Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
<ѻýҕl>Promising Data for Preop Checkpoint Inhibition in NSCLCѻýҕl> Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
<ѻýҕl>First-Ever Survival Bump in Relapsed Mesotheliomaѻýҕl> OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
<ѻýҕl>Dual Checkpoint Blockade No Help in PD-L1-High NSCLCѻýҕl> Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
<ѻýҕl>COVID Affects Cancer Care, Patients' Mental Healthѻýҕl> Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
<ѻýҕl>Chemo-Free Regimen Boosts OS in Mesotheliomaѻýҕl> Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo Aug 09, 2020
<ѻýҕl>Another ALK Drug Tops Crizotinib in First-Line NSCLCѻýҕl> Ensartinib doubled PFS over older standard, with improved CNS activity Aug 08, 2020
<ѻýҕl>Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Wordѻýҕl> Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure" Sep 10, 2019
<ѻýҕl>'Dirtier' Drugs Step Aside in RET-Positive NSCLCѻýҕl> Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
<ѻýҕl>TMB in Lung Cancer: 'Not Ready for Prime Time'ѻýҕl> No association between tumor mutational burden and outcomes in three trials Sep 09, 2019
<ѻýҕl>More Evidence that Screening Cuts Lung Cancer Deathsѻýҕl> Significantly lower risk in men and women Sep 26, 2018
<ѻýҕl>Newer ALK Inhibitor Tops Standard in NSCLCѻýҕl> Significant improvement in PFS with brigatinib after short follow-up Sep 26, 2018
<ѻýҕl>Anti-PD-L1 Drug Boosts Survival in Stage III NSCLCѻýҕl> New standard of care for patients with inoperable disease Sep 26, 2018
<ѻýҕl>Add-On Keytruda Boosts OS in Advanced Squamous Lung Cancerѻýҕl> Benefit seen across all subgroups, PD-L1 expression levels Sep 25, 2018
<ѻýҕl>No Survival Benefit with Cranial RT for NSCLCѻýҕl> Better disease-free survival, fewer brain mets Sep 25, 2018